GT Biopharma (GTBP) Short Interest Ratio & Short Volume → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free GTBP Stock Alerts $3.23 0.00 (0.00%) (As of 05/8/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media GT Biopharma Short Interest DataCurrent Short Volume3,300 sharesPrevious Short Volume8,800 sharesChange Vs. Previous Month-62.50%Dollar Volume Sold Short$12,408.00Short Interest Ratio / Days to Cover0.3Last Record DateApril 15, 2024Outstanding Shares1,380,000 sharesFloat Size1,240,000 sharesShort Percent of Float0.27%Today's Trading Volume1,945 sharesAverage Trading Volume11,289 sharesToday's Volume Vs. Average17% Short Selling GT Biopharma ? Sign up to receive the latest short interest report for GT Biopharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatGTBP Short Interest Over TimeGTBP Days to Cover Over TimeGTBP Percentage of Float Shorted Over Time Ad InvestorPlace$21,000 in profits in six weeks? On Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges.Click here for details. GT Biopharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20243,300 shares $12,408.00 -62.5%0.3%0.3 $3.76 3/31/20248,800 shares $38,984.00 +79.6%0.7%0.7 $4.43 3/15/20244,900 shares $22,687.00 -14.0%0.4%0.4 $4.63 2/29/20245,700 shares $24,282.00 +72.7%0.5%0.6 $4.26 2/15/20243,300 shares $13,200.00 +312.5%0.3%0.4 $4.00 1/31/2024800 shares $4,752.00 -98.6%0.1%0.1 $5.94 Get the Latest News and Ratings for GTBP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter. 1/15/202458,800 shares $13,171.20 +150.2%0.2%0.4 $0.22 12/31/202323,500 shares $5,992.50 -64.8%0.1%0.2 $0.26 12/15/202366,800 shares $16,472.88 +14.8%0.2%0.6 $0.25 11/30/202358,200 shares $12,804.00 -62.3%0.2%0.5 $0.22 11/15/2023154,300 shares $37,032.00 +16.1%0.4%1.2 $0.24 10/31/2023132,900 shares $33,278.16 -16.8%0.4%0.9 $0.25 10/15/2023159,800 shares $40,749.00 +56.4%0.4%1 $0.26 9/30/2023102,200 shares $24,640.42 +122.2%0.3%0.4 $0.24 9/15/202346,000 shares $12,880.00 -12.9%0.1%0.1 $0.28 8/31/202352,800 shares $13,780.80 -76.7%0.1%0.1 $0.26 8/15/2023227,000 shares $59,996.10 +22.3%0.6%0.4 $0.26 7/31/2023185,600 shares $51,040.00 -15.6%0.5%0.3 $0.28 7/15/2023219,900 shares $73,402.62 -1.7%0.6%0.4 $0.33 6/30/2023223,600 shares $69,763.20 +9.3%0.6%0.4 $0.31 6/15/2023204,600 shares $71,589.54 +53.5%0.6%0.5 $0.35 5/31/2023133,300 shares $30,019.16 -5.7%0.4%0.5 $0.23 5/15/2023141,400 shares $42,391.72 -12.8%0.4%0.9 $0.30 1/29/2021102,800 shares $47,550.14 +411.4%N/A0.1 $0.46 1/15/202127,100 shares $13,818.29 +118.6%N/A0 $0.51 12/31/202010,200 shares $4,386.00 -62.4%N/A0 $0.43 12/15/202027,100 shares $7,859.00 +118.6%N/A0 $0.29 11/30/202012,400 shares $2,168.76 -34.7%N/A0 $0.17 11/15/202019,000 shares $3,467.50 -54.2%N/A0 $0.18 10/30/202041,500 shares $8,590.50 +24.3%N/A0.1 $0.21 10/15/202033,400 shares $6,680.00 +59.8%N/A0 $0.20 9/30/202020,900 shares $3,657.50 +770.8%N/A0.1 $0.18 9/15/20202,400 shares $408.00 -81.5%N/A0 $0.17 8/31/202013,000 shares $2,382.90 +20.4%N/A0.1 $0.18 8/14/202010,800 shares $1,922.40 -26.5%N/A0 $0.18 7/31/202014,700 shares $2,940.00 -30.7%N/A0 $0.20 7/15/202021,200 shares $4,452.00 -0.5%N/A0.1 $0.21 6/30/202021,300 shares $2,982.00 -47.4%N/A0.1 $0.14 6/15/202040,500 shares $8,505.00 +130.1%N/A0.3 $0.21 5/29/202017,600 shares $3,560.48 +175.0%N/A0.1 $0.20$21,000 in profits in six weeks? (Ad)On Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges.Click here for details. GTBP Short Interest - Frequently Asked Questions What is GT Biopharma's current short interest? Short interest is the volume of GT Biopharma shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 3,300 shares of GTBP short. 0.27% of GT Biopharma's shares are currently sold short. Learn More on GT Biopharma's current short interest. What is a good short interest percentage for GT Biopharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.27% of GT Biopharma's floating shares are currently sold short. Is GT Biopharma's short interest increasing or decreasing? GT Biopharma saw a decline in short interest in April. As of April 15th, there was short interest totaling 3,300 shares, a decline of 62.5% from the previous total of 8,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is GT Biopharma's float size? GT Biopharma currently has issued a total of 1,380,000 shares. Some of GT Biopharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. GT Biopharma currently has a public float of 1,240,000 shares. How does GT Biopharma's short interest compare to its competitors? 0.27% of GT Biopharma's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to GT Biopharma: Longeveron Inc. (9.34%), Exicure, Inc. (2.01%), Artelo Biosciences, Inc. (0.19%), Genprex, Inc. (2.69%), Ensysce Biosciences, Inc. (0.14%), Tharimmune, Inc. (0.90%), NexImmune, Inc. (0.89%), Petros Pharmaceuticals, Inc. (1.69%), Lipella Pharmaceuticals Inc. (1.49%), Oragenics, Inc. (2.07%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short GT Biopharma stock? Short selling GTBP is an investing strategy that aims to generate trading profit from GT Biopharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against GT Biopharma? A short squeeze for GT Biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GTBP, which in turn drives the price of the stock up even further. How often is GT Biopharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GTBP, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: LGVN Short Interest Data XCUR Short Interest Data ARTL Short Interest Data GNPX Short Interest Data ENSC Short Interest Data THAR Short Interest Data NEXI Short Interest Data PTPI Short Interest Data LIPO Short Interest Data OGEN Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GTBP) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityWatch this FREE trading tutorial while it’s still availableInvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward Press